Personal information

Other IDs

SciProfiles: 1652582

Activities

Collapse all

Employment (1)

Weifang Medical University: Weifang, Shandong, CN

2020-08-01 to present (Department of Health Statistics)
Employment
Source: Self-asserted source
Qinghua Wang

Education and qualifications (1)

Tianjin Medical University: Tianjin, Tianjin, CN

2015-09-01 to 2020-07-01 | Ph.D. (Tianjin Cancer Institute)
Education
Source: Self-asserted source
Qinghua Wang

Works (10)

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers

International Immunopharmacology
2023-03 | Journal article | Author
DOI: 10.1016/j.intimp.2023.109821
Part of ISSN: 1567-5769
Contributors: Qinghua Wang; Wenjing Zhang; Yuxian Guo; Fuyan Shi; Yuting Li; Yujia Kong; Juncheng Lyu; Suzhen Wang
Source: Self-asserted source
Qinghua Wang

Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients

Cancers
2022-11 | Journal article | Author
DOI: 10.3390/cancers14225638
Contributors: Qinghua Wang; Na Tian; Wenjing Zhang; Zhijuan Lin; Fuyan Shi; Yujia Kong; Yanfeng Ren; Juncheng Lyu; Hao Qin; Hongqing Liu
Source: check_circle
Multidisciplinary Digital Publishing Institute

Identification and Validation of <i>RELN</i> Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer

Cells
2022-11 | Journal article | Author
DOI: 10.3390/cells11233841
Contributors: Zhenpeng Li; Xin Wang; Yi Yang; Fuyan Shi; Wenjing Zhang; Qinghua Wang; Suzhen Wang
Source: check_circle
Multidisciplinary Digital Publishing Institute

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer

Cancers
2022-07-19 | Journal article
DOI: 10.3390/cancers14143495
Part of ISSN: 2072-6694
Contributors: Qinghua Wang
Source: Self-asserted source
Qinghua Wang

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.

NPJ precision oncology
2022-06-23 | Journal article
DOI: 10.1038/s41698-022-00292-6
PMID: 35739249
PMC: PMC9226130
Source: Self-asserted source
Qinghua Wang

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma

Frontiers in Immunology
2022-01-11 | Journal article
DOI: 10.3389/fimmu.2021.798474
Part of ISSN: 1664-3224
Source: Self-asserted source
Qinghua Wang

An aging‐related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma

Cancer Science
2021-12-29 | Journal article
DOI: 10.1111/cas.15254
Part of ISSN: 1347-9032
Part of ISSN: 1349-7006
Source: Self-asserted source
Qinghua Wang

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer

Cancer Medicine
2021-12-04 | Journal article
DOI: 10.1002/cam4.4472
Part of ISSN: 2045-7634
Part of ISSN: 2045-7634
Source: Self-asserted source
Qinghua Wang

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma

Aging
2021-11-15 | Journal article
DOI: 10.18632/aging.203678
Part of ISSN: 1945-4589
Source: Self-asserted source
Qinghua Wang

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma

Frontiers in Immunology
2021-11-02 | Journal article
DOI: 10.3389/fimmu.2021.721409
Part of ISSN: 1664-3224
Source: Self-asserted source
Qinghua Wang
grade
Preferred source (of 2)‎
How many people are using ORCID?